Dolutegravir plus two nucleoside reverse transcriptase inhibitors versus efavirenz plus two nucleoside reverse transcriptase inhibitors as initial antiretroviral therapy for people with HIV: A systematic review

PLoS ONE

Volumn 11, Issue 10, 2016, Pages

  Rutherford, George W ^a   Horvath, Hacsi ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS DOLUTEGRAVIR PLUS LAMIVUDINE; ABACAVIR PLUS EFAVIRENZ PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DOLUTEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; DOLUTEGRAVIR; EFAVIRENZ; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADVERSE OUTCOME; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; RISK ASSESSMENT; RISK OF BIAS; SYSTEMATIC REVIEW; DRUG EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; META ANALYSIS; PROCEDURES;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84991474927     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0162775     Document Type: Review

References (25)

1. Kandel CE, Walmsley SL. Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Des Devel Ther. 2015; 9:3547-55. doi: 10.2147/DDDT.S84850 PMID: 26185421
2. Taha H, Das A, Das S. Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS. Infect Drug Resist. 2015; 8:339-52. doi: 10.2147/IDR.S68396 PMID: 26491363
3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. United States Department of Health and Human Services. Available: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
4. European AIDS Clinical Society. Guidelines 8.0. October 2015. Available: http://www.eacsociety.org/files/2015-eacsguidelines-8-0-english-rev-20160124.pdf.
5. British HIV Association (BHIVA). BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. Available: http://www.bhiva.org/documents/Guidelines/Treatment/2015/2015-treatment-guidelines.pdf.
6. Llibre JM, Pulido F, Garcia F, Garcia Deltoro M, Blanco JL, Delgado R. Genetic barrier to resistance for dolutegravir. AIDS Rev. 2015; 17(1):56-64. PMID: 25472016
7. Wainberg MA, Han YS. Will drug resistance against dolutegravir in initial therapy ever occur? Front Pharmacol. 2015; 6:90. doi: 10.3389/fphar.2015.00090 PMID: 25972810
8. Curtis L, Nichols G, Stainsby C, Lim J, Aylott A, Wynne B, et al. Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients. HIV Clin Trials. 2014; 15(5):199-208. doi: 10.1310/hct1505-199 PMID: 25350958
9. Stellbrink HJ, Reynes J, Lazzarin A, Voronin E, Pulido F, Felizarta F, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS. 2013; 27(11):1771-8. doi: 10.1097/QAD.0b013e3283612419 PMID: 23807273
10. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013; 381(9868):735-43. doi: 10.1016/S0140-6736(12)61853-4 PMID: 23306000
11. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013; 369(19):1807-18. doi: 10.1056/NEJMoa1215541 PMID: 24195548
12. Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014; 383(9936):2222-31. doi: 10.1016/S0140-6736(14)60084-2 PMID: 24698485
13. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013; 382(9893):700-8. doi: 10.1016/S0140-6736(13)61221-0 PMID: 23830355
14. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach - Second edition. Geneva: WHO, June 2016. Available: http://www.who.int/hiv/pub/arv/arv-2016/en/.
15. Ford N, Shubber Z, Pozniak A, Vitoria M, Doherty M, Kirby C, et al. Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials. J Acquir Immune Defic Syndr. 2015; 69(4):422-9. doi: 10.1097/QAI.0000000000000606 PMID: 25850607
16. Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Thery F, Shaffer N, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS. 2013; 27(9):1403-12. doi: 10.1097/QAD.0b013e32835f1db0 PMID: 23343913
17. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available: http://www.cochranehandbook.org.
18. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. doi: 10.1371/journal.pmed.1000097 PMID: 19621072
19. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011; 64(4):380-2. doi: 10.1016/j.jclinepi.2010.09.011 PMID: 21185693
20. van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012; 12(2):111-8. doi: 10.1016/S1473-3099(11)70290-0 PMID: 22018760
21. Walmsley S, Berenguer J, Khuong-Josses M-A, et al. Dolutegravir Regimen Statistically Superior to Efavirenz/Tenofovir/Emtricitabine: 96-Week Results From the SINGLE Study (ING114467) [Abstract number 543]. 21st Conference on Retroviruses and Opportunistic Infection, Boston, Massachusetts, 3-6 March 2014.
22. Raffi F, Rachlis A, Brinson C, Arasteh K, Gorgolas M, Brennan C, et al. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. AIDS. 2015; 29(2):167-74. doi: 10.1097/QAD.0000000000000519 PMID: 25387312
23. Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses MA, et al. Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial. J Acquir Immune Defic Syndr. 2015; 70(5):515-9. doi: 10.1097/QAI.0000000000000790 PMID: 26262777
24. World Health Organization. WHO Handbook for Guideline Development. 2nd edition. Geneva: World Health Organization, 2014. Available: http://www.who.int/kms/guidelines-review-committee/en/.
25. Sinclair D, Isba R, Kredo T, Zani B, Smith H, Garner P. World Health Organization guideline development: an evaluation. PloS One. 2013; 8(5):e63715. doi: 10.1371/journal.pone.0063715 PMID: 23741299